Centralized Pan-European Survey on the Undertreatment of Hypercholesterolemia in Patients Using Lipid Lowering Drugs–The CEPHEUS-Greece Survey

Abstract

Surveys evaluating plasma lipid goal attainment in patients with coronary heart disease (CHD) show that hypercholesterolemia is inadequately treated. CEPHEUS (CEntralized Pan-European survey on tHE Undertreatment of hypercholeSterolemia)-Greece was part of a European multicenter, cross-sectional survey to evaluate the proportion of patients on lipid-lowering drugs (LLDs) for ≥3 months, without dose modifications for at least 6 weeks, who reach their low-density lipoprotein—cholesterol (LDL-C) target. A total of 1321 Greek patients comprised the full analysis set (FAS); 28% were smokers, while 60.7%, 35.4%, 32.1%, and 25.1% had a history of hypertension, CHD, metabolic syndrome, and diabetes mellitus, respectively; 49.7% of the study population reached the Third Joint European Task Force (TJETF) LDL-C goals and 49.3% achieved the 2004-updated National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) targets. Hypercholesterolemia is suboptimally managed in Greece, with almost 50% of patients on LLDs not reaching the LDL-C target.